Galactose

Not All Food Intolerances Are the Same. Intoleran's Targeted Enzyme Solutions Can Help

Retrieved on: 
Tuesday, November 7, 2023
Galactose, Lactose, FODMAP, Fructose malabsorption, Fructose, Digestion, Prevalence, Lactose intolerance, Starch, Sucrose, Enzyme, Fructan, Food, Diagnosis, Food intolerance, Dairy

FORT LAUDERDALE, Fla., Nov. 7, 2023 /PRNewswire/ -- The team at Intoleran understands that food intolerances are both common and come in a variety of formats. Some, like lactose intolerance, are widespread and particularly common in certain demographics, such as those of East Asian or West African descent. The prevalence of other digestive conditions, such as fructose intolerance, is less well known, though the symptoms remain equally unpleasant.

Key Points: 
  • The prevalence of other digestive conditions, such as fructose intolerance, is less well known , though the symptoms remain equally unpleasant.
  • That's why Intoleran has invested in a diverse selection of enzyme products that help with different digestional concerns.
  • Not all food intolerances are the same, and our variety of enzymes offer an adaptable, clean, and effective way to enjoy your food again."
  • If they can help consumers meet that criteria, those individuals can truly enjoy their food again.

Intoleran Helps People on the Low-FODMAP Diet Shop With Confidence

Retrieved on: 
Monday, August 28, 2023
Diet, Life, Allergy, Human, Hope, Temporarily Yours, Enzyme, Lactose intolerance, Galactose, Fructan, Lactose, Fructose, Animal feed, Dairy, Dietary supplement

FORT LAUDERDALE, Fla., Aug. 28, 2023 /PRNewswire/ -- Food intolerances are common. While less dangerous than an allergy, they can be very painful, and many people seek ways to manage the symptoms. One of those is the low-FODMAP diet, which consists of temporarily limiting foods that contain fructans, galactans, lactose, fructose, and polyols.

Key Points: 
  • One of those is the low-FODMAP diet , which consists of temporarily limiting foods that contain fructans, galactans, lactose, fructose, and polyols.
  • "Low-FODMAP is a diet that helps you identify what foods your body struggles to digest," explains Harmen Treep, founder of Intoleran.
  • Treep is careful to clarify that digestive enzymes should be used alongside a healthy diet, not in place of one.
  • This enables everyone on the low-FODMAP diet of digestive self-discovery to execute each shopping trip with the confidence that they're creating a happier and healthier future for themselves.

Chinook Therapeutics Announces First Patient Enrolled in Pivotal Phase 3 BEYOND Study of Zigakibart (BION-1301) for Patients with IgA Nephropathy

Retrieved on: 
Friday, July 28, 2023
University, MBBS, Galactose, University of New South Wales, Medicine, Immunoglobulin A, Doctor of Philosophy, Dialysis, Kidney disease, Proteinuria, Patient, Kidney, FASN, Health, Therapy, Safety, Disease, Pharmaceutical industry, FRACP, IgA nephropathy, Chinook

SEATTLE, July 28, 2023 (GLOBE NEWSWIRE) -- Chinook Therapeutics, Inc. (Nasdaq: KDNY), a biopharmaceutical company focused on the discovery, development and commercialization of precision medicines for kidney diseases, today announced that the first patient with IgA nephropathy (IgAN) has been enrolled in the BEYOND study, a pivotal phase 3 clinical trial evaluating the safety and efficacy of zigakibart (BION-1301), a potentially disease-modifying anti-APRIL monoclonal antibody.

Key Points: 
  • SEATTLE, July 28, 2023 (GLOBE NEWSWIRE) -- Chinook Therapeutics, Inc. (Nasdaq: KDNY), a biopharmaceutical company focused on the discovery, development and commercialization of precision medicines for kidney diseases, today announced that the first patient with IgA nephropathy (IgAN) has been enrolled in the BEYOND study, a pivotal phase 3 clinical trial evaluating the safety and efficacy of zigakibart (BION-1301), a potentially disease-modifying anti-APRIL monoclonal antibody.
  • “Initiation of the phase 3 BEYOND study is an important step towards our goal of providing an innovative treatment option for patients with IgAN, a disease with high unmet need and limited treatment options,” said Eric Dobmeier, president and chief executive officer of Chinook Therapeutics.
  • “IgAN is the most common primary glomerular disease worldwide with limited treatment options currently available, causing many patients to progress to end-stage kidney disease, requiring dialysis or kidney transplant.
  • With the potential to be disease-modifying based on the encouraging results observed in the phase 1/2 study, I believe zigakibart could be an important new therapeutic treatment option for patients with IgAN.”

Applied Therapeutics Provides Regulatory Update on Galactosemia Program

Retrieved on: 
Tuesday, July 25, 2023
PIP, Galactose, New Drug Application, European Medicines Agency, NDA, Doctor of Philosophy, EMA, US, Galactitol, Patient, Advanz Pharma, MAA, FDA, Therapy, US FDA, Pharmaceutical industry, Galactosemia

NEW YORK, July 25, 2023 (GLOBE NEWSWIRE) -- Applied Therapeutics, Inc. (Nasdaq: APLT), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecular targets in indications of high unmet medical need, today provided a regulatory update on the Galactosemia program, including updates on the regulatory paths for govorestat (AT-007) in both the U.S. and Europe.

Key Points: 
  • NEW YORK, July 25, 2023 (GLOBE NEWSWIRE) -- Applied Therapeutics, Inc. (Nasdaq: APLT), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecular targets in indications of high unmet medical need, today provided a regulatory update on the Galactosemia program, including updates on the regulatory paths for govorestat (AT-007) in both the U.S. and Europe.
  • “We look forward to advancing our regulatory submissions in both the U.S. and Europe,” said Shoshana Shendelman, PhD, Founder and CEO of Applied Therapeutics.
  • “We believe that govorestat offers compelling efficacy alongside a favorable safety profile and represents a transformative treatment option for patients with Galactosemia.
  • There are currently no approved treatments for Galactosemia, and we hope to bring govorestat to patients as the first treatment for Galactosemia as soon as possible.”

Applied Therapeutics Reports First Quarter 2023 Financial Results

Retrieved on: 
Thursday, May 11, 2023
Cognition, Insurance, Partnership, Tremor, Galactose, Diabetic cardiomyopathy, NDA, Venrock, Doctor of Philosophy, Sale, Galactitol, Patient, Investment, MAA, Research, Therapy, Pharmaceutical industry, Cryptocurrency, Galactosemia, SORD

NEW YORK, May 11, 2023 (GLOBE NEWSWIRE) -- Applied Therapeutics, Inc. (Nasdaq: APLT), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecular targets in indications of high unmet medical need, today reported financial results for the first quarter ended March 31, 2023.

Key Points: 
  • NEW YORK, May 11, 2023 (GLOBE NEWSWIRE) -- Applied Therapeutics, Inc. (Nasdaq: APLT), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecular targets in indications of high unmet medical need, today reported financial results for the first quarter ended March 31, 2023.
  • “We are committed to bringing transformative therapies to patients with debilitating diseases and no treatment options, including Galactosemia, SORD Deficiency and Diabetic Cardiomyopathy,” said Shoshana Shendelman, PhD, Founder and CEO of Applied Therapeutics.
  • In April 2023, the Company announced consistent long-term clinical benefit from the ACTION-Galactosemia Kids Phase 3 study of govorestat.
  • Net loss for the first quarter of 2023 was $10.1 million, or $0.18 per basic and diluted common share, compared to a net loss of $23.1 million, or $0.88 per basic and diluted common share, for the first quarter 2022.

Sugar Rush: Scientists Discover Key Role of Glucose in Brain Activity

Retrieved on: 
Tuesday, April 18, 2023
Learning, Neuron, CRISPR, Human, Galactose, Alzheimer's disease, Department of Neurology, Xuanwu hospital, Glucose, University of California, San Francisco, Brain, Research, Cell, Doctor of Philosophy, Protein, Parkinson's disease, Glycolysis, Animal, Metabolism, MD, UCSF, Myenteric plexus, SAN, Blood, Chaumeil, Mouse, Liver, William Ewart Gladstone, Ageing, Gladstone Institutes, IPS, Neurology, Disease, Cell Reports, Medical imaging, Medical device

SAN FRANCISCO, April 18, 2023 /PRNewswire/ -- The human brain has a sweet tooth, burning through nearly one quarter of the body's sugar energy, or glucose, each day. Now, researchers at Gladstone Institutes and UC San Francisco (UCSF) have shed new light on exactly how neurons—the cells that send electrical signals through the brain—consume and metabolize glucose, as well as how these cells adapt to glucose shortages.

Key Points: 
  • Previously, scientists had suspected that much of the glucose used by the brain was metabolized by other brain cells called glia, which support the activity of neurons.
  • Past studies have established that the brain's uptake of glucose is decreased in the early stages of neurodegenerative diseases like Alzheimer's and Parkinson's.
  • Scientists have long debated what happens to glucose in the brain, and many have suggested that neurons themselves don't metabolize the sugar.
  • They engineered the animals' neurons— but not other brain cell types—to lack the proteins required for glucose import and glycolysis.

Intoleran Addresses Intolerances by Unlocking Healthy Digestion

Retrieved on: 
Friday, February 24, 2023
Starch, Food, Saliva, Lactose, Sucrose intolerance, Fructose, Nutrient, Stomach, Mouth, Enzyme, Irritable bowel syndrome, Galactose, IBS, Cramp, Extrapyramidal system, Lactase, Fructan, Southern Discomfort (Fabian Society pamphlets), Human, Glucose, Animal feed, Dairy

FORT LAUDERDALE, Fla., Feb. 24, 2023 /PRNewswire/ -- Digestive conditions, including food intolerances and IBS (irritable bowel syndrome), are common, with as many as 70 million individuals in the U.S. alone struggling with digestive diseases. In many cases, the issue revolves around the inability of the body to break down and process certain kinds of foods. Dutch health brand Intoleran is helping those with intolerances and IBS through its range of targeted digestive support products, all of which revolve around one key ingredient: digestive enzymes.

Key Points: 
  • In many cases, the issue revolves around the inability of the body to break down and process certain kinds of foods.
  • Dutch health brand Intoleran is helping those with intolerances and IBS through its range of targeted digestive support products, all of which revolve around one key ingredient: digestive enzymes.
  • "Digestive enzymes are the key to unlocking proper digestion," explains Intoleran owner Harmen Treep, "The body naturally produces these enzymes to break down certain kinds of foods using the key-lock principle."
  • Intoleran's range of enzyme products is extensive and includes enzymes to address intolerances for lactose, fructose, fructans, galactans, starch, and even histamines.

CHEW ANNOUNCES LAUNCH OF CUTTING-EDGE FASTFOOD HIGH-PERFORMANCE SPORTS NUTRITION PRODUCTS

Retrieved on: 
Tuesday, February 14, 2023
Ministry of Culture, Information, Sports and Youth Policy (Kyrgyzstan), Carbohydrate, Magnesium, Athlete, Fructose, Ironman, Electrolyte, Orange juice, Human power, Health, Food, Sport, Sodium, Galactose, Fast food, Glucose, Dietary supplement, Soft drink, Chewing, Hydrate

BOSTON, Feb. 14, 2023 /PRNewswire/ -- Chew, the food innovation lab committed to democratizing good food and beverage, today announced the launch of Fastfood™, a first-of-its-kind line of high-performance sports nutrition products engineered to fuel elite and amateur athletes.

Key Points: 
  • BOSTON, Feb. 14, 2023 /PRNewswire/ -- Chew, the food innovation lab committed to democratizing good food and beverage, today announced the launch of Fastfood™, a first-of-its-kind line of high-performance sports nutrition products engineered to fuel elite and amateur athletes.
  • Made from real food, Fastfood was engineered in collaboration with world-class endurance athletes and was created with an uncompromising focus on producing the highest-performing fuel possible.
  • Our science-fact approach at Chew is unparalleled within the industry, and we are extremely proud of what we were able to create with Fastfood.
  • The Fastfood line of products also includes an excellent Hydrator beverage mix, which provides optimal electrolytes and micro-nutrition for each occasion.

Managing a Food Intolerance During the Holidays? Use Intoleran

Retrieved on: 
Thursday, December 22, 2022
Holiday, Diet, Fructan, Lactose, Starch, Food, Carbohydrate, Fructose, Enzyme, IBS, FODMAPS, Human, Edible, Sucrose, Eating, Galactose, Food intolerance, Bloating, Dairy product

Those who manage food intolerances often adopt certain diets and shop in a way that limits or avoids troublesome foods.

Key Points: 
  • Those who manage food intolerances often adopt certain diets and shop in a way that limits or avoids troublesome foods.
  • This is useful for the majority of the year, but it can be challenging living with an intolerance during the holiday season.
  • For those managing a food intolerance this holiday season, Intoleran can help.
  • Intoleran products assist the digestive system by helping to properly digest food and, consequently, avoid many of the unpleasant side effects that come from food intolerances.

Intoleran Overcomes Lactose Intolerance

Retrieved on: 
Tuesday, November 29, 2022
Tablet, Human, Food, Milk, It's the Most Wonderful Time of the Year, Fructose, Cooking, Enzyme, Galactose, Sucrose, Butter, Degenerative disease, Capsule, Diet, Cheese, Holiday, Fructan, Lactase, Lactose intolerance, Christmas, Lactose, Eating, Dairy product

FORT LAUDERDALE, Fla., Nov. 29, 2022 /PRNewswire/ -- Lactose intolerance is a bothersome, painful, and intrusive digestive disorder. It develops when the body doesn't have enough lactase enzymes to properly digest lactose and absorb it into the small intestines. It's estimated that more than one in three Americans suffers from lactose intolerance, making it a prevalent concern — especially around the holidays. Cake, whipped cream, butter, and cheese are just a handful of popular holiday foods and ingredients that can set off a lactose intolerance. Even milk and cookies, Santa's signature favorite, is cause for concern.

Key Points: 
  • It's estimated that more than one in three Americans suffers from lactose intolerance, making it a prevalent concern especially around the holidays.
  • Cake, whipped cream, butter, and cheese are just a handful of popular holiday foods and ingredients that can set off a lactose intolerance .
  • Those with a minor intolerance can simply control their lactose intake with a low lactose diet.
  • Intoleran even has its revolutionary once a day capsules , which require consumption once every 24 hours and fight lactose intolerance around the clock.